CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-15 | Ramaswamy Vivek 10% owner | Option exercise | +832,453 | $12.68 | $10.6M | 34,486,208 |
| 2025-12-15 | Ramaswamy Vivek 10% owner | Sale | −353,745 | $22.05 | $7.8M | 34,132,463 |
| 2025-12-15 | Ramaswamy Vivek 10% owner | Other disposition | −478,708 | $22.05 | $10.6M | 33,653,755 |
| 2025-12-15 | Ramaswamy Vivek 10% owner | Option exercise · Stock Option (Right to Buy) | −832,453 | 22,150,227 | ||
| 2025-12-12 | Ramaswamy Vivek 10% owner | Option exercise | +4,672,724 | $12.68 | $59.3M | 38,326,479 |
| 2025-12-12 | Ramaswamy Vivek 10% owner | Sale | −1,975,858 | $21.96 | $43.4M | 36,350,621 |
| 2025-12-12 | Ramaswamy Vivek 10% owner | Other disposition | −2,696,866 | $21.96 | $59.2M | 33,653,755 |
| 2025-12-12 | Ramaswamy Vivek 10% owner | Option exercise · Stock Option (Right to Buy) | −4,672,724 | 22,982,680 | ||
| 2025-12-11 | Ramaswamy Vivek 10% owner | Option exercise | +1,869,691 | $12.68 | $23.7M | 35,523,447 |
| 2025-12-11 | Ramaswamy Vivek 10% owner | Sale | −774,142 | $21.64 | $16.8M | 34,749,305 |
| 2025-12-11 | Ramaswamy Vivek 10% owner | Other disposition | −1,095,550 | $21.64 | $23.7M | 33,653,755 |
| 2025-12-11 | Ramaswamy Vivek 10% owner | Option exercise · Stock Option (Right to Buy) | −1,869,691 | 27,655,404 | ||
| 2025-12-09 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,697,908 |
| 2025-12-09 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $20.85 | $4.2M | 1,497,908 |
| 2025-12-09 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 5,876,523 | ||
| 2025-11-20 | Pulik Richard CFO | Shares withheld for taxes | −1,235 | $20.27 | $25K | 388,273 |
| 2025-11-20 | Venker Eric President & Immunovant CEO | Shares withheld for taxes | −7,051 | $20.27 | $143K | 1,497,908 |
| 2025-11-19 | MANCHESTER KEITH S Director | Sale | −850,000 | $20.25 | $17.2M | 18,497,727 |
| 2025-11-19 | MANCHESTER KEITH S Director | Sale | −150,000 | $20.20 | $3.0M | 18,347,727 |
| 2025-11-19 | MANCHESTER KEITH S Director | Sale | −125,000 | $20.16 | $2.5M | 18,222,727 |
Page 15 of 29 · 570 trades